Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Phase 4Active Not RecruitingNCT03623633

Massachusetts General Hospital51 enrolled

Overview

Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene. Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued. This study will help us determine the optimal duration and relative efficacy of two oral antiresorptive medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Osteoporosis, Postmenopausal Osteoporosis

Interventions

Eligibility

Sex: FEMALEMin age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * women aged 45+ * postmenopausal * osteoporotic with high risk of fracture as per National Osteoporosis Foundation guidelines Exclusion Criteria: * no significant previous use of bone health modifying treatments * hip fracture within one year of enrollment * known congenital or acquired bone disease other than osteoporosis * significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease * abnormal calcium or parathyroid hormone level * serum vitamin D \<20 ng/dL * anemia (hematocrit \<32%) * history of malignancy (except non-melanoma skin carcinoma) * excessive alcohol use or substance abuse * extensive dental work involving extraction or dental implant within the past 6 months or in the upcoming 12 months * known contraindications to denosumab, alendronate, or raloxifene

Outcomes

Primary Outcomes

Serum c-telopeptide (CTX)

Change in serum CTX between month 12 and month 18

Time frame: Month 12 to 18 months

Bone mineral density (BMD)

Change in PA spine BMD between month 24 and month 36

Time frame: Month 24 to 36 months